Vera Therapeutics (VERA) Return on Capital Employed (2021 - 2026)
Vera Therapeutics posted quarterly Return on Capital Employed of 60.56% for Q1 2026, down 5106.0% year-on-year from 1.21% in Q1 2025, and down 9.94% on a QoQ basis from 55.09% in Q4 2025.
Vera Therapeutics (VERA) has 6 years of Return on Capital Employed data on file, last reported at 60.56% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 5106.0% year-over-year to 60.56%; the trailing twelve-month figure through Mar 2026 stood at 60.56% (down 5106.0% YoY), and the FY2025 full-year result was 49.16%, down 4097.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 60.56%, down from 55.09% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 6.56% in Q4 2024 and bottomed at 60.56% in Q1 2026.
- The 5-year median for Return on Capital Employed is 22.41% (2023), against an average of 26.66%.
- The widest annual swing landed in 2022, when Return on Capital Employed surged 6547 bps; it then slumped 5106 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 17.68% in 2022, then increased by 26 bps to 13.15% in 2023, then jumped by 50 bps to 6.56% in 2024, then tumbled by 739 bps to 55.09% in 2025, then decreased by 10 bps to 60.56% in 2026.
- The last three Return on Capital Employed figures came in at 60.56% (Q1 2026), 55.09% (Q4 2025), and 26.67% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Vera Therapeutics | 2.43 Bn | 1.83 Bn | - | -60.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -60.56% |
| Dec 31, 2025 | -55.09% |
| Sep 30, 2025 | -26.67% |
| Jun 30, 2025 | -17.98% |
| Mar 31, 2025 | -9.50% |
| Dec 31, 2024 | -6.56% |
| Sep 30, 2024 | -17.79% |
| Jun 30, 2024 | -9.08% |
| Mar 31, 2024 | -7.07% |
| Dec 31, 2023 | -13.15% |
| Sep 30, 2023 | -22.62% |
| Jun 30, 2023 | -22.70% |
| Mar 31, 2023 | -22.41% |
| Dec 31, 2022 | -17.68% |
| Sep 30, 2022 | -59.53% |
| Jun 30, 2022 | -40.05% |
| Mar 31, 2022 | -44.74% |
| Dec 31, 2021 | -43.13% |
| Sep 30, 2021 | -66.81% |
| Jun 30, 2021 | -80.55% |
| Mar 31, 2021 | -110.21% |